Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

• Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.

• The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.

• 2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks.

• The combination was well-tolerated.

• "Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit," added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer.

• Enrollment for the trial is stopped.

• The will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022.

• Price Action: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Biocept Stock Moves Higher On Collaboration With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients

• Histogen Stock Is Trading Higher As Emricasan Shows Complete, Early Resolution of COVID-19 Symptoms Compared To Placebo

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.